A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Schizophrenia

Interventions

DRUG

PF-05180999

Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules

DRUG

Placebo

Placebo oral solution or capsules

Trial Locations (1)

Pfizer Investigational Site, New Haven